{"prompt": "['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'The Investigator, for any reason, terminates the entire study, or terminates the study for that', 'subject or the attending physician requests that the subject be withdrawn for any medical reason', 'The Sponsor or the Regulatory Authority or the Ethics Committee, for any reason, terminates the', 'entire study or terminates the study for this site or this particular subject.', 'If a subject is discontinued from the study, the Investigator will, as far as possible, complete the end of', 'study visit (visit 9 or 10) CRF pages. The Investigator should try to ascertain the reason(s) for withdrawal,', \"while fully respecting the subject's rights.\", '16.2 Study Interruption', 'The Sponsor may consider study closure at the clinical site if the following occurs:', 'serious and/or persistent non-compliance with the Clinical Investigation Plan', 'inadequate collaboration of site personnel with CRO/Sponsor', 'administrative reasons', 'non-compliance with GCP, SOPs or regulatory requirements', 'lack of confidentiality and/or non-compliance with the contract spread with the Sponsor.', '17. Publication policy', 'All information obtained as a result of the study will be regarded as confidential.', 'The results of the clinical study will be documented in an integrated clinical study report according to', 'ISO 14155.', 'The Sponsor and the Investigator(s) agree that no publications presenting or discussing data and/or', 'results from clinical study sponsored by Helsinn Healthcare SA will take place until the participating', 'center has completed the study, the data have been interpreted, and the final report has been issued.', 'As a rule, the Sponsor is free to use the data collected in the sponsored study for world-wide scientific', 'product documentation, and for publication.', 'In general, the Sponsor has no objections if the Investigator publishes the results of the study sponsored', 'by Helsinn Healthcare SA. However, the Investigator is requested to provide the Sponsor with a copy of', 'the manuscript for review before submitting it to the publisher with a cover letter informing the Sponsor', 'about the intention to publish the study results. When permission for presentation or for publication is', 'granted, Investigators, prior to submission of a manuscript or abstract to the publisher, shall forward a', 'copy of said manuscript or abstract to the Sponsor who shall have 45 days to request any reasonable', 'amendment thereto, which shall be taken into due account and consideration by the Investigator.', 'CONFIDENTIAL', 'Page 38 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', \"The Sponsor is entitled to include as authors of the publication all Sponsor's personnel who contributed\", 'substantially to the theoretical or experimental work and also to take part in the decision that', \"establishes the order in which the authors' names will be given. Costs for publication must be regulated\", 'by written agreement between the parties.', 'For multicenter studies, the Investigators who will be quoted as authors of the publication(s) should be', 'agreed upon with the Sponsor. If publication of the results of the study, either in part or in full, is', 'prepared by the Sponsor, the Investigator(s) will be provided with a copy of the manuscript before the', 'submission to the publisher and asked to give approval of the document. Investigators will be asked in', 'writing if he/she accepts to be included as author of the publication. Answers should be sent in writing', 'to the Sponsor within a reasonable time limit (30 days). If no answer is received, it is assumed that the', \"Investigator agrees to the Sponsor's proposal.\", 'CONFIDENTIAL', 'Page 39 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', '18. Bibliography', '1. Campbell IR, Illingworth MH. Can patients wash during radiotherapy to the breast or chest wall? A', 'randomized controlled trial. Clin Oncol (R Coll Radiol). 1992; 4:78-82.', '2. Ryan JL, Bole C, Hickok JT et al. Post-treatment skin reactions reported by cancer patients differ by', 'race, not by treatment or expectations. Br J Cancer. 2007; 97: 14-21.', '3. Fromme EK, Eilers KM, Mori M, et al. How accurate is clinician reporting of chemotherapy adverse', 'effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30.', 'J Clin Oncol. 2004; 22: 3485-90.', '4. Elting LS, Keefe DM, Sonis ST et al. Patient-reported measurements of oral mucositis in head and', 'neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of', 'increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008;', '113:2704-13.', '5. Atherton PJ, Burger KN, Loprinzi CL et al. Using the Skindex-16 and Common Terminology Criteria', 'for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care', 'Cancer. 2012; 20: 1729-35.', '6.', 'Aistars J. The validity of skin care protocols followed by women with breast cancer receiving', 'external radiation. Clin J Oncol Nurs. 2006; 10: 487-92.', '7.', 'Salvo N, Barnes E, van Draanen J, et al. Prophylaxis and management of acute radiation-induced', 'skin reactions: a systematic review of the literature. Curr Oncol. 2010; 17: 94-112.', '8. Feight D, Baney T, Bruce S, McQuestion M. Putting evidence into practice. Clin J Oncol Nurs. 2011;', '15: 481-92.', '9.', 'Momm F, Weissenberger C, Bartelt S, Henke M. Moist skin care can diminish acute radiation-', 'induced skin toxicity. Strahlenther Onkol. 2003; 179: 708-12.', '10. Merchant TE, Bosley C, Smith J, et al. A phase III trial comparing an anionic phospholipid-based', 'cream and aloe vera-based gel in the prevention of radiation dermatitis in pediatric patients. Radiat', 'Oncol. 2007; 2:45.', '11. Palazzi M, Tomatis S, Orlandi E, Guzzo M, Sangalli C, Potepan P, Fantini S, Bergamini C, Gavazzi C,', \"Licitra L, Scaramellini G, Cantu' G, Olmi P. Effects of treatment intensification on acute local toxicity\", 'during radiotherapy for head and neck cancer: prospective observational study validating CTCAE,', 'version 3.0, scoring system. Int J Radiat Oncol Biol Phys 2008;70:330-337.', '12. Carrara M, Tomatis S, Bono A, et al. Automated segmentation of pigmented skin lesions in', 'multispectral imaging . Phys Med Biol. 2005; 21;N345-57.', 'CONFIDENTIAL', 'Page 40 of 53']\n\n###\n\n", "completion": "END"}